Home >> Signaling Pathways >> TGF-β / Smad Signaling

TGF-β / Smad Signaling

Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that regulates proliferation, migration, differentiation, and survival of many different cell types. Deletion or mutation of different members of the TGF-β family have been shown to cause vascular remodeling defect and absence of mural cell formation, leading to embryonic lethality or severe vascular disorders. TGF-β induces smooth muscle differentiation via Notch or SMAD2 and SMAD3 signaling in ES cells or in a neural crest stem cell line. TGF-β binds to TGF-βRI and to induce phosphorylation of SMAD2/3, thereby inhibiting proliferation, tube formation, and migration of endothelial cells (ECs).

TGF-β is a pluripotent cytokine with dual tumour-suppressive and tumour-promoting effects. TGF-β induces the epithelial-to-mesenchymal transition (EMT) leading to increased cell plasticity at the onset of cancer cell invasion and metastasis.

Targets for  TGF-β / Smad Signaling

Products for  TGF-β / Smad Signaling

  1. Cat.No. Product Name Information
  2. GC13890 (±)-Palmitoylcarnitine chloride intermediate in mitochondrial fatty acid oxidation (±)-Palmitoylcarnitine chloride  Chemical Structure
  3. GC10603 (-)-epicatechin gallate major catechin in green tea (-)-epicatechin gallate  Chemical Structure
  4. GC17242 (-)-epigallocatechin green tea epicatechin (-)-epigallocatechin  Chemical Structure
  5. GC14049 (-)-Epigallocatechin gallate (EGCG) (-)-Epigallocatechin Gallate sulfate (EGCG) is a major polyphenol in green tea that inhibits cell proliferation and induces apoptosis. In addition, it inhibits the activity of glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) .. (-)-Epigallocatechin gallate (EGCG)  Chemical Structure
  6. GC14012 (-)-Indolactam V A protein kinase C activator (-)-Indolactam V  Chemical Structure
  7. GC18062 1,2-Dilauroyl-sn-glycerol A longchain DAG 1,2-Dilauroyl-sn-glycerol  Chemical Structure
  8. GC14134 1,2-Dimyristoyl-sn-glycerol A longchain DAG 1,2-Dimyristoyl-sn-glycerol  Chemical Structure
  9. GC13877 1,2-Dipalmitoyl-sn-glycerol

    weak activator of PKC

    1,2-Dipalmitoyl-sn-glycerol  Chemical Structure
  10. GC12662 1,2-Distearoyl-sn-glycerol A diacylglycerol 1,2-Distearoyl-sn-glycerol  Chemical Structure
  11. GC12172 1-Naphthyl PP1 Src family kinases inhibitor 1-Naphthyl PP1  Chemical Structure
  12. GC41863 10,11-dehydro Curvularin A natural mycotoxin 10,11-dehydro Curvularin  Chemical Structure
  13. GN10444 12-O-tetradecanoyl phorbol-13-acetate

    A PKC activator

    12-O-tetradecanoyl phorbol-13-acetate  Chemical Structure
  14. GC13927 A 77-01 A potent ALK5 inhibitor A 77-01  Chemical Structure
  15. GC10166 A 83-01 A TGF-β type I receptor inhibitor A 83-01  Chemical Structure
  16. GC35210 A 83-01 sodium salt A potent inhibitor of TGF-β type I receptor ALK5 kinase A 83-01 sodium salt  Chemical Structure
  17. GC60037 A-3 hydrochloride A-3 hydrochloride is a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases. A-3 hydrochloride  Chemical Structure
  18. GC15579 Adaphostin P210bcr/abl tyrosine kinase inhibitor Adaphostin  Chemical Structure
  19. GC16475 Afuresertib pan-AKT inhibitor Afuresertib  Chemical Structure
  20. GC42747 Afuresertib (hydrochloride) Afuresertib is a selective, orally bioavailable inhibitor of Akt1, 2, and 3 with Ki values of 0.08, 2, and 2.6 nM, respectively. Afuresertib (hydrochloride)  Chemical Structure
  21. GC65294 ALK2-IN-2 ALK2-IN-2 is a potent and selective inhibitor of activin receptor-like kinase 2 (ALK2) with an IC50 of 9 nM, and over 700-fold selectivity against ALK3. ALK2-IN-2  Chemical Structure
  22. GC11050 ALK5 Inhibitor II (hydrochloride) ALK5 inhibitor ALK5 Inhibitor II (hydrochloride)  Chemical Structure
  23. GC34300 AR-13324 analog mesylate AR-13324 analog mesylate  Chemical Structure
  24. GC19034 AR-13324 mesylate

    AR-13324 is a potent inhibitor of ROCK I and ROCK II that has been shown to induce morphologic changes in cultured human and porcine TM cells at low concentration.

    AR-13324 mesylate  Chemical Structure
  25. GC31959 AS2521780 AS2521780 is a novel PKCθ selective inhibitor with an IC50 of 0.48 nM. AS2521780  Chemical Structure
  26. GC32703 Asciminib (ABL001) Asciminib (ABL001) (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib (ABL001)  Chemical Structure
  27. GC64462 Asciminib hydrochloride Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib hydrochloride  Chemical Structure
  28. GN10534 Asiaticoside Asiaticoside  Chemical Structure
  29. GC17712 AT13148 Multi-AGC kinase inhibitor,ATP-competitive AT13148  Chemical Structure
  30. GC64815 Aurothiomalate sodium Aurothiomalate sodium is a potent and selective oncogenic PKCι signaling inhibitor. Aurothiomalate sodium  Chemical Structure
  31. GC50589 AZ 12799734 Potent TGF-βRI inhibitor AZ 12799734  Chemical Structure
  32. GC35442 Azaindole 1 Azaindole 1 (Azaindole 1; TC-S 7001) is an orally active and ATP-competitive ROCK inhibitor with IC50s of 0.6 and 1.1nM for human ROCK-1 and ROCK-2, respectively. Azaindole 1  Chemical Structure
  33. GC35462 Bafetinib

    Bcr-Abl/Lyn tyrosine kinase inhibitor

    Bafetinib  Chemical Structure
  34. GC33343 BCR-ABL-IN-1 BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia. BCR-ABL-IN-1  Chemical Structure
  35. GC33368 BCR-ABL-IN-2 BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. BCR-ABL-IN-2  Chemical Structure
  36. GC32868 BDP5290

    BDP5290 is a potent inhibitor of ROCK and MRCK with IC50 values of 17nM, 230nM, 123nM and 100nM for MRCKβ, ROCK1, ROCK2, respectively .

    BDP5290  Chemical Structure
  37. GC34493 BIBF0775 BIBF0775 is a potent and selective transforming growth factor β (TGFβ) type I receptor (Alk5) inhibitor with an IC50 of 34 nM. BIBF0775  Chemical Structure
  38. GC62868 BIO-013077-01 BIO-013077-01 is a pyrazole TGF-β inhibitor. BIO-013077-01  Chemical Structure
  39. GC12135 Bisindolylmaleimide II protein kinase C (PKC) inhibitor Bisindolylmaleimide II  Chemical Structure
  40. GC14716 Bisindolylmaleimide IV protein kinase C (PKC) inhibitor Bisindolylmaleimide IV  Chemical Structure
  41. GC17239 Bisindolylmaleimide V negative control for protein kinase C (PKC)-inhibitory activity Bisindolylmaleimide V  Chemical Structure
  42. GC13226 Bisindolylmaleimide VIII (acetate) A protein kinase C (PKC) inhibitor Bisindolylmaleimide VIII (acetate)  Chemical Structure
  43. GC18354 Bisindolylmaleimide X (hydrochloride) Bisindolylmaleimide X is a cell-permeable, reversible, ATP-competitive protein kinase C (PKC) inhibitor (IC50 = 15 nM, rat brain PKC). Bisindolylmaleimide X (hydrochloride)  Chemical Structure
  44. GC35530 BJE6-106 BJE6-106 (B106) is a potent, selective 3rd generation PKCδ inhibitor with an IC50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC50=50 μM). BJE6-106  Chemical Structure
  45. GC50593 BMP signaling agonist sb4

    Potent BMP4 agonist

    BMP signaling agonist sb4  Chemical Structure
  46. GC13343 Bosutinib (SKI-606) Bosutinib (SKI-606) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively. Bosutinib (SKI-606)  Chemical Structure
  47. GC40080 Bosutinib-d8 Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib by GC- or LC-MS. Bosutinib-d8  Chemical Structure
  48. GC17670 Bryostatin 1 PKC activator Bryostatin 1  Chemical Structure
  49. GC12842 Bryostatin 2 Protein kinase C (PKC) activator Bryostatin 2  Chemical Structure
  50. GC12695 Bryostatin 3 protein kinase C activator Bryostatin 3  Chemical Structure
  51. GC16539 Butaprost A selective agonist for the EP2 receptors Butaprost  Chemical Structure
  52. GC11605 C-1 C-1 is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. C-1 also used as a ROCK inhibitor. C-1  Chemical Structure
  53. GC43105 C8 Ceramide (d18:1.8:0) C8 Ceramide (d18:1.8:0) (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8 Ceramide (d18:1.8:0)  Chemical Structure
  54. GC11159 Calphostin C

    protein kinase C inhibitor

    Calphostin C  Chemical Structure
  55. GC62612 CC-90005 CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC50 of 8 nM. CC-90005  Chemical Structure
  56. GC38898 CCG-222740 CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor. CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis. CCG-222740  Chemical Structure
  57. GC35651 Cenisertib Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia. Cenisertib  Chemical Structure
  58. GC18521 Cercosporin Cercosporin is a pigmented phytotoxin isolated from the fungus C. Cercosporin  Chemical Structure
  59. GC10687 CGP 53353 PKCβII inhibitor CGP 53353  Chemical Structure
  60. GC14650 CGP60474 A CDK inhibitor CGP60474  Chemical Structure
  61. GC32250 Chebulinic acid An ellagitannin with diverse biological activities Chebulinic acid  Chemical Structure
  62. GN10463 Chelerythrine Chelerythrine  Chemical Structure
  63. GC13065 Chelerythrine Chloride Potent inhibitor of PKC and Bcl-xL Chelerythrine Chloride  Chemical Structure
  64. GC35682 CHMFL-ABL/KIT-155 CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis. CHMFL-ABL/KIT-155  Chemical Structure
  65. GC43286 CMPD101 A GRK2 and GRK3 inhibitor CMPD101  Chemical Structure
  66. GC50704 CRT 0066854 hydrochloride CRT 0066854 hydrochloride is a potent and selective atypical PKCs inhibitor. CRT 0066854 hydrochloride  Chemical Structure
  67. GC45414 CRT0066854   CRT0066854  Chemical Structure
  68. GC35753 CT-721 CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities. CT-721  Chemical Structure
  69. GC33351 CZC-8004 (CZC-00008004) CZC-8004 (CZC-00008004) (CZC-00008004), an aminopyrimidine, is a pan-kinase inhibitor. CZC-8004 (CZC-00008004) can bind a range of tyrosine kinases, including EGFR and VEGFR2 with IC50 values of 650 and 437 nM, respectively. CZC-8004 (CZC-00008004)  Chemical Structure
  70. GC17591 D-erythro-Sphingosine (synthetic) D-erythro-Sphingosine (synthetic) (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (synthetic) (Erythrosphingosine) is also a PP2A activator. D-erythro-Sphingosine (synthetic)  Chemical Structure
  71. GN10336 Daphnetin Daphnetin  Chemical Structure
  72. GC38186 Daphnoretin A coumarin with diverse biological activities Daphnoretin  Chemical Structure
  73. GC35812 Dasatinib hydrochloride A potent and dual AblWT/Src inhibitor Dasatinib hydrochloride  Chemical Structure
  74. GC15884 Dasatinib Monohydrate Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases. Dasatinib Monohydrate  Chemical Structure
  75. GC14007 DCC-2036 (Rebastinib) DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit. DCC-2036 (Rebastinib)  Chemical Structure
  76. GC38388 DCPLA-ME DCPLA-ME, the methyl ester form of DCPLA, is a potent PKCε activator for use in the treatment of neurodegenerative diseases. DCPLA-ME  Chemical Structure
  77. GC31892 Decursin ((+)-Decursin) Decursin ((+)-Decursin) ((+)-Decursin ((+)-Decursin)) is a potent anti-tumor agent. Decursin ((+)-Decursin)  Chemical Structure
  78. GC38085 Decursinol angelate Decursinol angelate, a cytotoxic and protein kinase C (PKC) activating agent from the root of Angelica gigas, possesses anti-tumor and anti-inflammatory activities. Decursinol angelate  Chemical Structure
  79. GC16354 Dequalinium Chloride anti-tumor agent and PKC inhibitor Dequalinium Chloride  Chemical Structure
  80. GC38482 Desmethylglycitein Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities.Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity. Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1). Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes. Desmethylglycitein  Chemical Structure
  81. GC17767 Dihydrosphingosine Dihydrosphingosine is a potent inhibitor of PKC and phospholipase A2 (PLA2). Dihydrosphingosine  Chemical Structure
  82. GC34060 Disitertide (P144) Disitertide (P144) (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) (P144) is also a PI3K inhibitor and an apoptosis inducer. Disitertide (P144)  Chemical Structure
  83. GC68333 Disitertide diammonium Disitertide diammonium  Chemical Structure
  84. GC60782 Disitertide TFA Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) TFA is also a PI3K inhibitor and an apoptosis inducer. Disitertide TFA  Chemical Structure
  85. GC14298 DMH-1 Selective BMP ALK2 receptor DMH-1  Chemical Structure
  86. GC17243 Dorsomorphin (Compound C) Dorsomorphin (Compound C) (Compound C) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (Compound C) (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin (Compound C) induces autophagy. Dorsomorphin (Compound C)  Chemical Structure
  87. GC12560 Dorsomorphin (Compound C) 2HCl Dorsomorphin (Compound C) 2HCl (BML-275 dihydrochloride; Compound C dihydrochloride) is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin (Compound C) 2HCl inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin (Compound C) 2HCl induces autophagy. Dorsomorphin (Compound C) 2HCl  Chemical Structure
  88. GC35897 DPH A potent cell permeable c-Abl activator DPH  Chemical Structure
  89. GC32914 EMT inhibitor-1 EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities. EMT inhibitor-1  Chemical Structure
  90. GC11499 Enzastaurin (LY317615) Enzastaurin (LY317615) (LY317615) is a potent and selective PKCβ inhibitor with an IC50 of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε. Enzastaurin (LY317615)  Chemical Structure
  91. GC65329 EW-7195 EW-7195 is a potent and selective ALK5 (TGFβR1) inhibitor with an IC50 of 4.83 nM. EW-7195 has >300-fold selectivity for ALK5 over p38α. EW-7195 efficiently inhibits TGF-β1-induced Smad signaling, epithelial-to-mesenchymal transition (EMT) and breast tumour metastasis to the lung. EW-7195  Chemical Structure
  92. GC13354 EW-7197 EW-7197 (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC50 of 12.9 nM. EW-7197 also inhibits ALK2 and ALK4 (IC50 of 17.3 nM) at nanomolar concentrations. EW-7197 has potently antimetastatic activity and anticancer effect. EW-7197  Chemical Structure
  93. GC13869 Fasudil Calcium antagonist Fasudil  Chemical Structure
  94. GC14289 Fasudil (HA-1077) HCl Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil (HA-1077) HCl is also a potent Ca2+ channel antagonist and vasodilator. Fasudil (HA-1077) HCl  Chemical Structure
  95. GC32867 Flumatinib (HHGV678) Flumatinib (HHGV678) (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib (HHGV678) inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively. Flumatinib (HHGV678)  Chemical Structure
  96. GC13914 Flumatinib mesylate PDGRFβ inhibitor Flumatinib mesylate  Chemical Structure
  97. GC12027 FR 236924 FR 236924 (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. FR 236924  Chemical Structure
  98. GC65539 Fresolimumab Fresolimumab (GC1008) is a high-affinity fully human monoclonal antibody that neutralizes the active form of human TGFβ1, TGFβ2, and TGFβ3. Fresolimumab  Chemical Structure
  99. GC15431 GF 109203X (Bisindolylmaleimide I) GF 109203X (GF109203X) is a highly selective, cell-permeable, and reversible protein kinase C (PKC) inhibitor with a Ki of 14 nM. GF 109203X  (Bisindolylmaleimide I)  Chemical Structure
  100. GC36167 GMB-475 GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein. GMB-475  Chemical Structure
  101. GC10858 GNF 2 Bcr-Abl inhibitor GNF 2  Chemical Structure

Items 1 to 100 of 280 total

per page
  1. 1
  2. 2
  3. 3

Set Descending Direction